Genetically defined mouse models offer an important tool to identify critical secondary genetic alterations with relevance to human cancer pathogenesis. We used newly generated MMTV-Cre105Ayn mice to inactivate p53 and/or Rb strictly in the mammary epithelium, and to determine recurrent genomic changes associated with deficiencies of these genes. p53 inactivation led to formation of estrogen receptor-positive raloxifene-responsive mammary carcinomas with features of luminal subtype B. Rb deficiency was insufficient to initiate carcinogenesis but promoted genomic instability and growth rate of neoplasms associated with p53 inactivation. Genome-wide analysis of mammary carcinomas identified a recurrent amplification at chromosome band 9A1, a locus orthologous to human 11q22, which contains protooncogenes cIAP1 (Birc2), cIAP2 (Birc3) and Yap1. It is interesting that this amplicon was preferentially detected in carcinomas carrying wild-type Rb. However, all three genes were overexpressed in carcinomas with p53 and Rb inactivation, likely due to E2F-mediated transactivation, and cooperated in carcinogenesis according to gene knockdown experiments. These findings establish a model of luminal subtype B mammary carcinoma, identify critical role of cIAP1, cIAP2 and Yap1 co-expression in mammary carcinogenesis and provide an explanation for the lack of recurrent amplifications of cIAP1, cIAP2 and Yap1 in some tumors with frequent Rb deficiency, such as mammary carcinoma.
Introduction
Breast cancer is the most commonly diagnosed malignancy and the second leading cause of cancer-related deaths among women in the United States of America (Jemal et al., 2009) . p53 and Rb and their pathways are frequently altered in breast cancer. p53 is a transcription factor that regulates genes critical for cell cycle, apoptosis, senescence and DNA repair, thus preventing genomic instability (Riley et al., 2008; Meek, 2009 ). Mutation of p53 is the most common genetic abnormality found in human cancer, and occurs in 20-40% of sporadic breast carcinomas (Borresen-Dale, 2003) . Furthermore, p53 is mutated in individuals with Li-Fraumeni syndrome, a heritable condition in which early-onset breast cancers are the most prevalent cancer types (Malkin, 1994) . According to gene expression profiling, p53 mutations are most frequently associated with basal-like/estrogen receptor (ER)-negative (82%), ERBB2/HER2 overexpressing/ER-negative (71%) and luminal/ER-positive subtype B (40%) breast cancers (Sorlie et al., 2001) , all of which have poor prognosis (Sorlie et al., 2001 (Sorlie et al., , 2003 Hu et al., 2006) .
Mice homozygous for the p53-null allele (p53 À/À ) develop lymphomas or sarcomas within first 3 months (Donehower et al., 1992; Jacks et al., 1994) . Development of some mammary tumors has been observed in p53 þ /À mice, but only on the BALB/c background (Kuperwasser et al., 2000) . With the development of Cre-loxP technology, spontaneous mammary carcinogenesis has been observed after inactivation of wild-type p53 by either its deletion (Lin et al., 2004; Liu et al., 2007) or expression of a dominant-negative form carrying a p53.R270H point mutation (Wijnhoven et al., 2005) . Unfortunately, the interpretation of experiments has been somewhat complicated by the formation of lymphomas and/or other neoplasms due to expression of the Cre transgene in lymphocytes and other tissues.
Rb is essential for cell cycle control and exerts diverse effects on cell proliferation, survival and differentiation (Burkhart and Sage, 2008) . More recently the role of Rb in control of genomic instability has been shown in cell culture experiments and in a mouse model of liver neoplasia (Knudsen et al., 2006; Reed et al., 2009) . The observation that Rb is inactivated in 20-35% of human breast cancers, suggests that it has an important role in the pathogenesis of these neoplasms (Scambia et al., 2006; Bosco and Knudsen, 2007) . In addition, other defects in Rb pathway components, such as Cyclin D1 overexpression, and p16 INK4A loss are frequently observed in human breast cancer (Geradts and Wilson, 1996; Roy and Thompson, 2006) . However, in serial transplantations of Rb mutant mammary anlagen no significant differences were found in outgrowth of Rbdeficient and wild-type epithelia (Robinson et al., 2001) . At the same time, transgenic mice expressing cyclin D1 in the mammary gland, hence deprived of functional Rb family proteins (Rb, p107 and p130), develop mammary neoplasms (Wang et al., 1994) . Accordingly, it has been reported that inactivation of the whole Rb family by T 121m, a fragment of SV40 T antigen, also leads to mammary carcinogenesis (Simin et al., 2004) .
In agreement with the potential cooperation between p53 and Rb inactivation, p53 deficiency results in acceleration of mammary carcinogenesis in the T 121m model (Simin et al., 2004) , as well as in transgenic mice expressing SV40 large T antigen (Li et al., 2000) , which inactivates both p53 and all proteins of Rb family. However, it remains unclear whether selective inactivation of Rb has any effect on cancer initiation or progression.
To ensure mammary epithelium-restricted Cre expression, we have established a new FVB/N MMTV-Cre transgenic mouse line (MMTV-Cre105Ayn) that does not express Cre in lymphocytes and other tissues. Using this line we show that conditional inactivation of p53 results in ER-positive mammary carcinomas that carry recurrent amplification of cellular inhibitor of apoptosis (cIAP)1, cIAP2 and Yap1. Rb inactivation alone is insufficient to initiate mammary carcinogenesis, but promotes genetic instability and accelerates neoplastic growth. It is interesting that lack of Rb suppresses genomic amplification of cIAP1, cIAP2 and Yap1. However, expression levels of these genes remain elevated and their knockdown decreases tumorigenicity, thereby indicating critical importance of the cIAP1, cIAP2 and Yap1 in mammary carcinogenesis.
Results

Generation of MMTV-Cre transgenic mice
To avoid genetic background variations and frequent lymphomas due to Cre expression in lymphocytes and other tissues we generated mice expressing Cre under the control of MMTV-LTR ( Figure 1a ) and screened founders for exclusive expression of Cre in the mammary epithelium after their crosses with Gt(ROSA) 26SorTM1sor reporter mice. One out of five tested lines, FVB/N Tg(MMTV-Cre)105Ayn, expressed Cre selectively in the mammary epithelium ( Supplementary  Table 1 and Supplementary Figure 1 ) Furthermore, no lymphomas or other non-mammary neoplasms were observed in crosses of this line with p53 floxP/floxP mice. Therefore, it has been chosen for all subsequent experiments and will be described as MMTV-Cre.
Inactivation of p53 in mammary epithelium leads to neoplastic lesions and Rb loss accelerates carcinogenesis Conditional inactivation of p53 was sufficient for mammary carcinogenesis in our model. A total of 8 out of 16 (50%) p53 MEÀ/À mice (see Materials and Methods for abbreviations) and none out of eight (0%) Rb MEÀ/À mice developed mammary neoplasms by 700 days of age ( Figure 1b ). A total of 15 out of 17 (88%) p53 MEÀ/À Rb MEÀ/À mice developed mammary neoplasms. All neoplasms arising in p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice have lost both copies of p53 and p53 and Rb, respectively (Supplementary Figure 2) . The median tumor-free survival of p53 MEÀ/À Rb MEÀ/À mice was significantly shorter than that of p53 MEÀ/À mice (P ¼ 0.0058). Thus, although Rb inactivation alone is insufficient for initiation of mammary carcinogenesis, p53 and Rb cooperate in suppression of carcinogenesis.
In agreement with the low frequency (1% of cells) of Cre expression in the mammary glands, the majority of mice developed only one mammary tumor (Supplementary Table 2 ). A total of 3 out of 27 (11%) and 4 out of 40 (10%) of p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice, respectively, developed lung metastasis. A total of 8 out of 27 (30%) and 10 out of 43 (23%) neoplasms in p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice, respectively, were relatively well-differentiated carcinomas (Figure 1c and Supplementary Table 2 ). In these tumors neoplastic cells formed solid, glandular and trabecular patterns and were separated by desmoplastic stroma. One tumor in each group was an adenosquamous carcinoma. The remaining tumors were poorly differentiated carcinomas and consisted of cytokeratin (CK) 8-positive epithelioid, spindle or polygonal, frequently pleomorphic, cells. The degree of pleomorphism was particularly notable in 2 out of 18 (11%) and 9 out of 32 (28%) neoplasms from p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice, respectively. The frequency of poorly differentiated carcinomas of p53 MEÀ/À Rb MEÀ/À mice was also somewhat higher than that of p53 MEÀ/À mice (67 versus 75%). However, both parameters were not statistically significant (Fisher's exact test two-sided P ¼ 0.2866 and 0.579, respectively). A total of 7 out of 32 poorly differentiated neoplasms of p53 MEÀ/À Rb MEÀ/À mice, but none out of 18 in p53 MEÀ/À mice contained significant (over 5%) areas of solid or glandular differentiation (Fisher's exact test two-sided P ¼ 0.04). Smooth muscle actin, CK5-or CK6-positive cells were present in one third of neoplasms, but did not exceed 3-5% of tumor cells. As expected from the loss of Rb function, neoplastic cells deficient for both p53 and Rb proliferated significantly faster than cells with p53 deficiency alone in histologically comparable areas ( Supplementary Figure 3 ). In agreement with preferentially luminal differentiation of the neoplasms, all of them (10 out of 10 in each group) expressed ERa in at least 25% of cells ( Figure 1c ). All tumors also expressed a downstream target of ERa, progesterone receptor (PR). At the same time, as characteristic for luminal subtype B carcinomas (Hu et al., 2006) , all tumors expressed mitotic checkpoint protein Mad2.
Mammary neoplasms respond to hormone therapy with a selective ER modulator In addition to detection of ER and PR in all mammary carcinomas by immunohistochemical analysis (Figure 1c ), we confirmed their expression in the cell lines MCN1, MCN2 and MCN3 established from those tumors (Figure 2a and Supplementary Table 3 ). To determine whether tumors respond to hormone therapy, effects of raloxifene, a selective ER modulator, which competes with endogenous estrogen for ERa binding (Sporn et al., 2004) , were tested in all three mammary carcinoma cell lines. According to the BrdU incorporation assay, raloxifene treatment resulted in a dose-dependent cell proliferation decrease in all three cell lines within concentration range from 10 nM to 1 mM Figure 2b ). Raloxifene also significantly delayed the neoplastic growth after mammary fat pad transplantation of MCN1 (P ¼ 0.0132) and MCN2 (P ¼ 0.0088; Figure 2c ). Taken together, these results confirm functional status of ERa in p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mouse models of mammary carcinoma.
Rb inactivation affects the pattern of secondary genetic alterations and increases genomic instability of mammary cancer associated with p53 deficiency To determine whether there were any specific genetic aberrations associated with mammary carcinomas in our models, comparative genomic hybridization array (aCGH) analyses were performed on DNA isolated from these neoplasms ( Figure 3 ). The genome of p53-deficient tumors was characterized by a recurrent amplification (five out of six tumors) at chromosomal band 9A1. In addition, chromosome bands 12C2-12F1 were deleted in five out of six mammary tumors from p53 MEÀ/À mice. It is interesting that in mammary tumors from p53 MEÀ/À Rb MEÀ/À mice (Figure 3a ), only one out of six tumors had a genomic amplification of 9A1 and none carried the deletion at 12C2-12F1. At the same time, five out of six (83%) mammary tumors from p53 MEÀ/À Rb MEÀ/À mice had amplification at chromosomes 6A1 and 6A2, whereas only two out of six (33%) mammary tumors from p53 MEÀ/À mice had amplification of these regions. Analysis by spectral karyotyping showed chromosomal aberrations that resulted in a net gain of chromosome 9A1 (Figure 3b ). aCGH data also showed that neoplasms from p53 MEÀ/À Rb MEÀ/À mice contained 20% more genomic imbalances compared with those in p53 MEÀ/À mice ( Figure 3c ). Consistently, spectral karyotyping analysis showed a high degree of aneuploidy and an increased rate of structural chromosomal instability (P ¼ 0.0213) in carcinomas from p53 MEÀ/À Rb MEÀ/À mice. This was measured as the presence of de novo non-clonal chromosome aberrations per cell (Figure 3b and Supplementary  Table 4 ).
Previous studies showed that E2F family, one of the main Rb downstream effectors, mediates DNA double strand break accumulation and contribute to mitotic defects and genomic instability (Pickering and Kowalik, 2006) , at least in part by activating Mad2 expression (Hernando et al., 2004) . Consistently with those observations, higher levels of E2F1, E2F3 and Mad2 were found in primary tumors from p53 MEÀ/À Rb MEÀ/À mice as compared with p53 MEÀ/À mice (Figure 4a ). Accordingly, tumor cells deficient for both p53 and Rb contained higher subpopulation with multiple centrosomes ( Figure 4b ) and double strand breaks ( Figure 4c ) according to g-tubulin staining and neutral comet assays, respectively. cIAP1, cIAP2 and Yap1 are regulated by E2F and cooperate in mammary carcinogenesis The chromosome band 9A1 is orthologous to human chromosome band 11q22, which is frequently amplified in human cancers (Overholtzer et al., 2006) and contains the protooncogenes cIAP1 (Birc2), cIAP2 (Birc3) and Yap1. Given the potential importance of these genes for human cancer we fine mapped the extent of the amplicon by showing lack of amplification of the flanking genes Tmem123 (Porimin) and Pgr (PR) genes by quantitative real-time PCR (qPCR) in tumors from p53 MEÀ/À mice (Figure 5a ). At the same time, qPCR was also used to confirm the aCGH results indicating lack of recurrent amplification of cIAP1, cIAP2 and Yap1 in carcinomas of p53 MEÀ/À Rb MEÀ/À mice.
It is of note that mRNA expression analyses showed that all three genes were similarly overexpressed in carcinomas of both p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice Figure 2 Mammary neoplasms respond to hormone therapy with raloxifene. (a) Western blot of ERa, and PR in MCN1, MCN2, MCN3 and MCF7 cell lines. To normalize for differences in loading, the blots were stripped and reprobed with mouse anti-Gapdh monoclonal antibody. (b) Effects of raloxifene on proliferation of mammary carcinoma cells as determined by BrdU incorporation and compared with control (mean ± s.d., n ¼ 3 in each group, Po0.05, indicated as *). All MCN cell lines are p53 null and have either two ( þ / þ ) or no (À/À) functional copies of the Rb gene. (c) Effects of raloxifene on tumor growth in vivo. MCN1 and MCN2 cells (10 6 ) were transplanted to cleared fad pad of 4-week-old FVB mice. According to the tumor volume measurements 12 days after transplantation, raloxifene (raloxifene þ ) significantly delays the tumor growth of MCN1 (P ¼ 0.0132) and MCN2 (P ¼ 0.0088) cells as compared with control group without raloxifene treatment (raloxifeneÀ).
Rb role in mammary cancer L Cheng et al ( Figure 5b ). As promoter regions of all three genes contain E2F binding sites ( Supplementary Figure 4) , E2F regulation of cIAP1, cIAP2 and Yap1 expression was tested by E2F1 knockdown. Consistent with the Rb/E2F regulation model, knockdown of E2F1 by siRNA in mammary carcinoma cell lines resulted in significant (Po0.05) downregulation of cIAP1, cIAP2 and Yap1 24 h after transfection (Figure 5c ). Cre-loxPmediated inactivation of Rb alone or together with p53 in primary mammary epithelial cells resulted in increased expression of cIAP1 and cIAP2 at 24 h followed by further increase at 72 h (Figure 5c ). Inactivation of p53 alone had only marginal effect on the expression of cIAP1 and led to decreased expression of cIAP2. Furthermore, induction of p53 expression by treatment with doxorubicin did not result in decreased expression of cIAP1 and cIAP2 as compared with p53-deficient cells (Supplementary Figure 5 ). Yap1 expression also increased after Rb inactivation but lacked significant increase immediately after simultaneous inactivation of p53 and Rb genes. Computational analysis of the Yap1 gene identified a putative p53 binding site in the intron 1 ( Supplementary Figure 4) . Consistently, decrease and increase of Yap1 expression was observed after deletion and doxorubicin-induced upregulation of p53, respectively (Figure 5c and Supplementary Figure 5C ). Taken together, these observations indicate that defective Rb/E2F pathway was likely to be sufficient for immediate upregulation of cIAP1 and cIAP2, as well as later overexpression of Yap1, thereby avoiding the need for genomic amplification of these genes during mammary carcinogenesis.
To further elucidate the roles of cIAP1, cIAP2 and Yap1 in mammary carcinomas we used siRNA to knockdown the expression of these genes ( Figure 6 and Supplementary Figure 6 ). Downregulation of each gene, individually, resulted in significant decrease in cell proliferation and increase in apoptosis (Figure 6a ). The effect was even more pronounced after two or all three genes were inactivated simultaneously. To test tumorigenic properties of cIAP1, cIAP2 and Yap1, respective siRNAs were delivered with atelocollagen to mammary carcinoma cells transplanted to the mammary fat pad. Downregulation of each gene, individually, resulted in deceleration of tumor growth. Similarly to cell culture results, suppression of tumor growth was most pronounced by simultaneous downregulation of two and particularly all three genes. Taken together, these observations show that cIAP1, cIAP2 and Yap1 are important for mammary carcinogenesis associated with p53 deficiency and cooperate to promote neoplastic growth.
Discussion
Human sporadic cancers have a broad repertoire of genetic changes and understanding of their contributions to major pathways defects is of critical importance. Mouse models of human cancer have been shown to serve as useful systems to facilitate identification of genetic alterations essential for carcinogenesis by comparative oncogenomic approaches (Kim et al., 2006; Zender et al., 2006; Maser et al., 2007) . During the past two decades it has become increasingly clear that different cancer phenotypes of mouse models may reflect distinct initiating genetic and epigenetic alterations (Cardiff et al., 2000) . Indeed, combination of p53 and Brca1 somatic inactivation results in the formation of tumors mimicking human BRCA1-mutated ERnegative basal-like cancer (Liu et al., 2007) . At the same time inactivation of p53 together with E-cadherin leads to ER-negative metastatic lobular mammary carcinoma (Derksen et al., 2006) . Mammary neoplasms associated with p53 deficiency alone were reported to be either ER-negative (Liu et al., 2007) or both ER-negative and -positive, depending on MMTV or WAP promoter used to express Cre in deleter mouse strains (Lin et al., 2004) .
Since available mammary epithelium-specific deleter strains express Cre in lymphoid and other tissues, we have established an additional MMTV-Cre strain with a highly mammary epithelium-restrictive expression pattern. It is interesting that unlike other MMTV-Crebased models and likely because of transgene positional effects, the cancers forming in our model are ERpositive and have no or very limited non-luminal differentiation typical for such tumor types as adenomyoepthelial, adenosquamous and basal-like carcinomas. Thus interpretation of cancer phenotypes is also likely to be affected by variations in transgene expression patterns and transformation of distinct cell lineages and their subpopulations.
On the basis of the expression of markers for luminal differentiation, such as ER and CK8, combined with p53-deficient status, as well as expression of Mad2 and cIAP2 (Frasor et al., 2009) , this model may represent an attractive tool for studies of human luminal subtype B breast cancers (Sorlie et al., 2001; Hu et al., 2006) . This model is also particularly amenable to further experiments because of responsiveness of mammary carcinomas to an estrogen antagonist, as well as availability of established syngeneic mammary carcinoma cell lines. Considering the 50% frequency of mammary carcinomas and long latency period of carcinogenesis in p53 MEÀ/À mice, they are particularly well suited for assessment of other endogenous and exogenous factors that are expected to accelerate carcinogenesis.
Our studies confirmed previous observations that sporadic inactivation of Rb alone is insufficient for the initiation of mammary carcinogenesis (Robinson et al., 2001) . Furthermore, the use of a Cre-loxP approach allowed direct genetic demonstration that Rb loss-offunction, without inactivation of p107 and/or p130, leads to acceleration of mammary carcinogenesis associated with p53 inactivation. At least in part, this effect may be explained by increased proliferation rate of Rbdeficient neoplastic cells.
p53 and Rb pathways are extensively connected and their inactivation frequently cooperates during carcinogenesis presumably by abrogating E2F-induced p53-mediated apoptosis or senescence (Sherr and McCormick, 2002; Sherr, 2004) . Our study illuminates genomic instability as another mechanism of p53 and Rb cooperation. Genomic instability is a hallmark of most human cancers. Although much attention has been focused on the role of p53 in the maintenance of genomic stability, an accumulating body of evidence indicates Rb as another important player (Knudsen et al., 2006) . Rb inactivation has been shown to promote genomic instability by uncoupling cell cycle progression from mitotic control (Hernando et al., 2004) and by mediating DNA double strand break accumulation (Pickering and Kowalik, 2006) in cell culture models. In vivo, Rb loss results in ectopic cell cycle, compromises ploidy control in mouse liver (Mayhew et al., 2005) and promotes hepatocarcinogenesis (Mayhew et al., 2007; Reed et al., 2009) . Our study extends these observations by showing higher levels of the E2F downstream target Mad2, higher rates of double strand DNA breaks and centrosome amplification and overall increase in chro-Rb role in mammary cancer L Cheng et al mosomal structural instability in mammary carcinomas deficient for both p53 and Rb. Further studies should determine whether Rb loss leads to similar consequences in the normal mammary epithelium. It also remains to be shown whether observed increase in phenotypical diversity and trend towards increase of cellular polymorphism and poorer differentiations in carcinomas of p53 MEÀ/À Rb MEÀ/À mice are a result of elevated genomic instability associated with Rb deficiency. Using aCGH, we identified a number of recurrent genetic alterations in our mammary carcinoma models. It is likely that each of these alterations has individual contributions to carcinogenesis. The amplification of 9A1 locus is of a particular interest because it includes protooncogenes, such as cIAP1, cIAP2 and Yap1. cIAP1 and cIAP2 encoded proteins contain baculoviral IAP repeat domain and are key regulators of apoptosis, cytokinesis and signal transduction. Both genes are commonly amplified in many human cancers (reviewed in LaCasse et al., 2008) . Yap1 contains a WW domain and binds to the SRC Homology 3 domain of the tyrosine kinase Yes. It has been shown to be expressed in common solid tumors (Steinhardt et al., 2008) and to have tumorigenic properties in both liver (Zender et al., 2006) and breast cancer (Overholtzer et al., 2006) . Considering the high frequency of 9A1 locus amplification in neoplasms of p53 MEÀ/À mice, this model may prove to be very valuable for further studies of mechanisms involved in amplification of human orthologous genes on chromosome 11q22.
Amplification of both cIAP1 and Yap1 was observed in four out of seven tumors in a transplantable mouse model of liver cancer based on transduction of p53-deficient fetal hepatoblasts with Myc retrovirus (Zender et al., 2006) . At the same time, amplification of cIAP1 and cIAP2, together with matrix metalloproteinase MMP13, was observed in 5 out of 41 osteosarcomas (Ma et al., 2009) . Yap1 amplification was detected in 1 out of 15 mammary tumors of MMTV-Cre Brca1 floxP/À p53 þ /À mice. However, amplification of Yap1 was detected in none of over 100 sporadic human breast cancers (Overholtzer et al., 2006) . Our observations of E2F-mediated control of cIAP1, cIAP2 and Yap1 may explain how dysfunctional Rb/E2F pathway may substitute for recurrent amplification of these genes. As alterations in the Rb pathway are quite common in mouse and human tumors, including mammary carcinomas, this mechanism may also explain differences in frequencies of cIAP1, cIAP2 and Yap1 amplification among various tumor types.
Our results show that cIAP1, cIAP2 and Yap1 overexpression is critical for mammary carcinogenesis associated with p53 mutations. It is of interest that overexpression of cIAP2 has been recently reported to be associated with luminal subtype B of breast cancer (Frasor et al., 2009) . Further studies will examine whether tumors of this subtype also overexpress cIAP1 and Yap1. Cooperation among cIAP1, cIAP2 and Yap1 in promoting tumorigenicity observed in our work is consistent with previously reported cooperation between cIAP1 and Yap1 in hepatocarinogenesis (Zender et al., 2006) . Recently a broad variety of IAP molecule antagonists have been developed (LaCasse et al., 2008) . Our results indicate that their application may be particularly effective in combination with downregulation of Yap1.
In summary, we established a new mouse model of sporadic ER-positive luminal mammary carcinoma associated with p53 inactivation. We showed that Rb deficiency accelerates mammary carcinogenesis and leads to increased genomic instability and to a different spectrum of recurrent genomic alterations. Of particular interest, genes of chromosome band 9A1, namely cIAP1, cIAP2 and Yap1, were shown to be important for mammary carcinogenesis. We proposed the E2Fmediated mechanism of their regulation and established cooperation among all three genes in promoting neoplastic growth. These observations provide the basis for further elucidation of cooperation of these genes in human cancers and lay the ground for rational development of therapeutic approaches in preclinical settings.
Materials and methods
Mouse breeding
Male MMTV-Cre transgenic mice were crossed with female p53 floxP/floxP (p53 L/L ), Rb floxP/floxP (Rb L/L ) or p53 floxP/floxP Rb floxP/floxP (p53 L/L Rb L/L ) mice, respectively, to achieve inactivation of p53 or Rb alone or together in the mammary epithelium. The resulting MMTV-Cre, p53 L/L , MMTV-Cre, Rb L/L and MMTV-Cre, p53 L/L Rb L/L mice, were designated as p53 MEÀ/À , Rb MEÀ/À and p53 MEÀ/À Rb MEÀ/À , respectively. Reporter mice Gt(ROSA) 26SorTM1sor (Chai et al., 2000 were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Mice carrying conditional alleles for p53 (floxed exon 2-10) and/or Rb (floxed exon 19) were described elsewhere (Marino et al., 2000; Jonkers et al., 2001) . All mice were placed on FVB/N genetic background by at least 10 backcrosses and only nulliparous females were used. All mice were maintained identically, following recommendations of the Institutional Laboratory Animal Use and Care Committee. Figure 4 Rb inactivation promotes genomic instability. (a) (Left) Western blot of E2F1, E2F3 and Mad2 in primary tumor cells from p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice. (Right) Relative Mad2 mRNA expression in carcinomas of p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice (mean ± s.d., 2.9 ± 2.1 versus 6.3 ± 4.0, n ¼ 10, P ¼ 0.0411, indicated as *). (b) (Top) Immunofluorescence staining (g-tubulin) of centrosomes in primary tumor cells from p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice. (Bottom left) Percentage of cells with more than 2 centrosomes is higher in cells from p53 MEÀ/À Rb MEÀ/À mice, as compared with that in cells from p53 MEÀ/À mice (75.8±9.0 versus 49.6±12.0, n ¼ 10, P ¼ 0.0083). (Bottom right) Tumor cells from p53 MEÀ/À Rb MEÀ/À mice have higher average number of centrosomes per cell than that from p53 MEÀ/À mice (4.96±0.76 versus 3.34±0.90, n ¼ 10, P ¼ 0.0152,). (c) (Left) Representative images of neutral comet assay with primary tumor cells from p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice. (Right) Tumor cells from p53 MEÀ/À Rb MEÀ/À mice have higher percentage of cells with comet tail as compared with p53 MEÀ/À (18.9 ± 1.3 versus 11.5 ± 3.3, n ¼ 10, P ¼ 0.0232).
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Pathological evaluation
Mice were euthanized when mammary tumors reached 1 cm in diameter, at 700 days of age or after becoming moribund. Animals were evaluated grossly during necropsy and subjected to the systematic pathological assessment as descried earlier (Flesken-Nikitin et al., 2003; Zhou et al., 2006 Zhou et al., , 2007 . All lesions were identified according to the Classification of Neoplasia of Genetically Engineered Mice (Cardiff et al., 2000) endorsed by the Mouse Models of Human Cancer Consortium (National Institute of Health/National Cancer Institute).
Histochemical analyses
Immunohistochemical analysis of paraffin sections of paraformaldehyde-fixed tissue was done by a modified avidin-biotin-peroxidase (Vector Laboratories, Burlingame, CA, USA) technique with antigen retrieval as described earlier Figure 5 Copy number and expression of cIAP1, cIAP2 and Yap1 in mammary carcinomas of p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice. (a) (Top) The map of the genes in the chromosome 9A1 region under study. (Bottom) Mammary carcinomas from p53 MEÀ/À mice have higher cIAP1, cIAP2 and Yap1 gene copy number than those from p53 MEÀ/À Rb MEÀ/À mice (mean±s.d., n ¼ 10 in each group). cIAP1: 17.6±19.2 versus 3.1±3.1; cIAP2: 20.3±19.7 versus 3.1±2.4 and Yap1: 19.03±17.96 versus 4.08±2.95, respectively. *indicates Po0.05. DNA copy number of Tmem123 and Pgr is similar between the cells from these two different types of mice (Tmem123: 1.88 ± 1.36 versus 1.78 ± 1.41 and Pgr: 1.87 ± 1.6 versus 1.72 ± 1.32). qPCR. (b) (Left) Overexpression of cIAP1, cIAP2 and Yap1 in mammary carcinomas from both p53 MEÀ/À and p53 MEÀ/À Rb MEÀ/À mice as compared with the wild-type (WT) mammary epithelium (mean ± s.d., n ¼ 10 in each group) cIAP1: 7.80 ± 8.61 (p53 MEÀ/À ), 12.30 ± 15.30 (p53 MEÀ/À Rb MEÀ/À ) versus 1.05 ± 0.13 (WT); cIAP2: 6.31±10.89 (p53 MEÀ/À ), 5.73±6.72 (p53 MEÀ/À Rb MEÀ/À ) versus 1.06±0.18 (WT) and Yap1: 18.29±27.12 (p53 MEÀ/À ), 19.12±20.15 (p53 MEÀ/À Rb MEÀ/À ) versus 1.16±0.19 (WT), * indicates Po0.05. qRT-PCR. (Right) Western blot of cIAP1 and Yap1 in MCN1, MCN2, MCN3 cells and primary culture of wild-type mammary epithelium (WT). (c) Expression of E2F1, cIAP1, cIAP2 and Yap1 after E2F1 knockdown by E2F1 siRNA as compared with scrambled siRNA control (mean ± s.d., n ¼ 4 in each group; Po0.05 is indicated as *). All MCN cell lines are p53 null and have either two ( þ / þ ) or no (À/À) functional copies of the Rb gene (top left). Relative expression (mean ± s.d., n ¼ 4 in each group) of cIAP1 (top right), cIAP2 (bottom left) and Yap1 (bottom right) collected at 24 and 72 h after treatment of mammary epithelium cells from floxed p53 (p53 L/L ), Rb (Rb L/L ) or p53 and Rb (p53 L/L Rb L/L ) mice with blank Adenovirus (blank) or AdCre (Po0.05 is indicated as *). qRT-PCR. Figure 6 cIAP1, cIAP2 and Yap1 cooperate in mammary carcinogenesis. (a) Downregulation of either cIAP1, cIAP2 or Yap1 by siRNA in primary mammary carcinoma cells leads to decreased cell proliferation (left) and increase of apoptosis (right) as compared with scrambled siRNA control. Both effects are more pronounced after inactivation of any two or all three genes. (mean±s.d., n ¼ 4 in each group, Po0.05, indicated as *). (b) Effect of cIAP1, cIAP2 or Yap1 knockdown on tumor growth (mean ± s.d., n ¼ 4 in each group). According to the tumor volume measurements 17 days after transplantation, downregulation of cIAP1, cIAP2 and Yap1 by siRNA in MCN1 mammary carcinoma cells decelerates tumor growth as compared with control (P ¼ 0.014, P ¼ 0.0056 and P ¼ 0.0091, respectively). Combination of cIAP1 and cIAP2, cIAP1 and Yap1, or all three genes further delays the tumor growth (P ¼ 0.0022, P ¼ 0.0073 and P ¼ 0.0069, n ¼ 4, respectively).
Rb role in mammary cancer L Cheng et al (Zhou et al., 2006) . Primary antibodies to the following antigens were used: CK5 (Covance, Berkeley, CA, USA, 1:1000), CK6, (Covance, 1:300), CK8 (Developmental Studies Hybridoma Bank, University of Iowa, 1:50), Ki67 (Novocastra Laboratories, Bannockburn, IL, USA, 1:1000) smooth muscle actin (Spring Bioscience, Fermont, CA, USA, 1:300), ERa (Santa Cruz Laboratories, Santa Cruz, CA, USA, 1:200) and progesterone (PR; Santa Cruz Laboratories, 1:200). Enzymatic detection of bacterial b-galactosidase was performed as previously described (Flesken-Nikitin et al., 2003; Zhou et al., 2007) . All quantitative analyses were performed on digitally captured images as described in (Zhou et al., 2006) .
Cell culture
To prepare mammary epithelial cells, mammary glands were dissected from 3-6-month-old female mice. The tissue was placed in EpiCult-B medium (StemCell Technologies, Vancouver, BC, USA) with 5% fetal bovine serum (Sigma, St Louis, MO, USA), 300 U/ml collagenase (StemCell Technologies) and 100 U/ml hyaluronidase (StemCell Technologies) for 8 h at 37 1C. The dissociated tissue fragments were resuspended in 0.64% NH 4 Cl for lysis of the red blood cells. The further dissociation of fragments was obtained by their gentle pipetting in 0.25% trypsin (Cellgro, Manassas, VA, USA) for 2 min, followed by placing into 5 mg/ml dispase (StemCell Technologies) and 0.1 mg/ml DNase (StemCell Technologies) for 3 min and filtration through a 40-mm mesh. Derivation of MCN1, MCN2, MCN3 and MCN9 cells is described in Supplementary Table 3 . Cells were cultured in HAM's medium (Dulbecco's Modified Eagle's Medium/F12, 50/50 Mix; Cellgro), supplemented with 5% fetal bovine serum, 2 mM L-Glutamine, 1 mM Na-Pyruvate and 5 mg/ml insulin. MCF7 (American Type Culture Collection, Manassas, VA, USA), a human breast cancer cell line, was cultured in Dulbecco's Modified Eagle's Medium containing 10% fetal bovine serum and 10 mg/ml insulin. All cell lines were maintained in 5% CO 2 atmosphere at 371C.
Mammary fat pad transplantation, raloxifene and siRNA treatment
The number 4 pair of mammary glands of anaesthetized, 3-week-old female FVB mice were surgically exposed under sterile condition. 10 6 tumor cells in 100 ml sterile PBS were injected into the cleared fat pad using a Hamilton syringe and 25-gauge needle and tumor formation was monitored daily. Tumors were measured in three dimensions with a caliper, and the volume was calculated using the formula: V ¼ p/6 (L Â W Â H). Raloxifene (10 mg/g body weight in DMSO) was applied subcutaneously to mice every two days from second day after cell transplantation. For siRNA treatment, 100 ml 5mM siRNA was mixed with 100 ml atelocollagen (AteloGene Systemic Use; Koken, Tokyo, Japan) and administered locally as described (Minakuchi et al., 2004) . All mice were monitored daily and the experiments were terminated after tumors reached volume 0.8 cm 3 .
Comparative genomic hybridization assay
Genomic DNA of mammary tumors from p53 MEÀ/À and p53 ME-/-Rb ME-/mice was assayed by comparative genomic hybridization. Genomic DNA from FVB female mice was used as a control. Genomic DNA was extracted using DNeasy Tissue Kit (Qiagen, Valencia, CA, USA). Mouse BAC genomic arrays, each composed of 6500 RPCI-23 or PRCI-24 clones, were prepared in the Roswell Park Cancer Institute Microarray Core Facility (Buffalo, NY, USA). Data were analyzed as previously described (Zhou et al., 2006) .
Other methods, including generation of transgene, genotyping, western blotting analyses, proliferation and apoptosis assays, neutral comet and centrosome assays, AdCre, E2F1 knockdown and doxorubicin treatment assays, quantitative PCR and RT-PCR, spectral karyotyping and statistical analyses, are described in Supplementary Information.
